Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa).
Lisa A. Carey(University of North Carolina at Chapel Hill), Clifford A. Hudis(American Society of Clinical Oncology), Maggie C.U. Cheang(Institute of Cancer Research), Lyndsay N. Harris(National Institutes of Health), Ian E. Krop(Yale Cancer Center), Charles M. Perou(University of North Carolina at Chapel Hill), Chau T. Dang(Memorial Sloan Kettering Cancer Center), Sara M. Tolaney(Harvard University), N. Lynn Henry(University of Utah), Eric P. Winer(University of Vermont), Donald A. Berry(Berry & Associates (United States)), Brandy Pitcher(Duke Medical Center), Katherine A. Hoadley(University of North Carolina at Chapel Hill), William T. Barry(Harvard University), Carey K. Anders(Duke University)
Cited by 24
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer
|Cell|2018|2.8k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k